Dermatologic Therapy

Article	Citations
Cutaneous signs in COVID ‐19 patients: A review	153
Oral manifestations ofCOVID‐19 disease: A review article	142
Cutaneous manifestations and considerations in COVID ‐19 pandemic: A systematic review	77
Biologics increase the risk of SARS ‐ CoV ‐2 infection and hospitalization, but not ICU admissi	74
Herpes zoster might be an indicator for latent COVID 19 infection	62
COVID‐19 related masks increase severity of both acne (maskne) and rosacea (mask rosacea): Multi‐center, real‐life, telemedical, and observational prospective study	60
Increased flare of acne caused by long‐time mask wearing during COVID ‐19 pandemic among general population	59
The clinics of HHV ‐6 infection in COVID ‐19 pandemic: Pityriasis rosea and Kawasaki disease	55
Inconveniences due to the use of face masks during the COVID ‐19 pandemic: A survey study of 876 young people	53
Evaluation of skin problems and dermatology life quality index in health care workers who use personal protection measures during COVID ‐19 pandemic	47
Cutaneous sıde‐effects of the potential COVID‐19 drugs	47
The effect of the “stay‐at‐home” policy on requests for dermatology outpatient clinic visits after the COVID ‐19 outbreak	47
Back to the basics: Propolis and COVID ‐19	46
Cutaneous manifestations in hospitalized patients diagnosed as COVID ‐19	46
Telogen effluvium associated with COVID‐19 infection	43
Relative changes in the pattern of diseases presenting in dermatology outpatient clinic in the era of theCOVID‐19 pandemic	43
Unraveling the mystery of Covid‐19 cytokine storm: From skin to organ systems	42
Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti‐ interleukin ‐17 treatment: A real‐life 52‐week retrospective study	42
The impact of air pollution on skin and related disorders: A comprehensive review	42
COVID‐19 knowledge prevents biologics discontinuation: Data from an Italian multicenter survey duringRED‐ZONEdeclaration	41
Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study	40
Cutaneous manifestations of the Coronavirus Disease 2019 ( COVID ‐19): A brief review	40
Covid‐19 and exacerbation of psoriasis	39
Maculopapular eruptions associated to COVID ‐19: A subanalysis of the COVID‐Piel study	39
Cutaneous adverse reactions after COVID‐19 vaccines in a cohort of 2740 Italian subjects: An observational study	39

Urticaria and COVID ‐19: A review	38
The top 10 cosmeceuticals for facial hyperpigmentation	38
Internet and social media use in dermatology patients: Search behavior and impact on patient‐physician relationship	37
Efficacy and safety of risankizumab in psoriasis patients who failed anti‐IL ‐17, anti‐12/23 and/or anti IL ‐23: Preliminary data	37
Psychodermatology of vitiligo: Psychological impact and consequences	36
Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during theCOVID‐19 pandemic	36
Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: A network meta‐analysis	36
Real‐life experience of guselkumab in patients with psoriasis	35
Novel coronavirus disease 2019 (COVID‐19) and neurodegenerative disorders	34
Dupilumab and COVID ‐19: What should we expect?	33
Comparative analysis of perceived stress in dermatologists and other physicians during national lock‐down and COVID ‐19 pandemic with exploration of possible risk fa	33
Evaluation of the effects of COVID‐19 pandemic on hair diseases through a web‐based questionnaire	33
COVID ‐19 vaccine‐induced urticarial vasculitis	33
Drug survival in the treatment of generalized pustular psoriasis: A retrospective multicenter study	33
Treatment of COVID ‐19 with pentoxifylline: Could it be a potential adjuvant therapy?	32
Upadacitinib improved alopecia areata in a patient with atopic dermatitis: A case report	32
Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study	32
Psoriasis flare after influenza vaccination in Covid‐19 era: A report of four cases from a single center	31
Mucosal involvement in a COVID ‐19‐positive patient: A case report	31
Ixekizumab: An efficacious treatment for both psoriasis and hidradenitis suppurativa	31
Teledermatology and chronic skin diseases: Real life experience in a Southern Italian Dermatologic Centre	31
Teledermatologic monitoring for chronic cutaneous autoimmune diseases with smartworking during COVID‐19 emergency in a tertiary center in Italy	31
Herpes zoster as a potential complication of coronavirus disease 2019	31
Emerging role of nanocarriers based topical delivery of anti‐fungal agents in combating growing fungal infections	31
Efficacy of resveratrol in the wound healing process by reducing oxidative stress and promoting fibroblast cell proliferation and migration	30
Tildrakizumab for the treatment of moderate to severe psoriasis: Results from a single center preliminary real‐life study	30
Angiotensin II receptors: Impact for COVID ‐19 severity	30
COVID‐19 and psoriasis: Should we fear for patients treated with biologics?	30
Gender differences in cutaneous melanoma: Demographics, prognostic factors, and survival outcomes	30
Safety of low‐dose oral minoxidil treatment for hair loss. A systematic review and pooled‐analysis of individual patient data	29
Onset of vitiligo in a psoriasis patient on ixekizumab	29
Are erythema multiforme and urticaria related to a better outcome of COVID ‐19?	29
Chilblain‐like lesions in pediatrics dermatological outpatients during the COVID ‐19 outbreak	29
Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine	29
COVID‐19 and exacerbation of dermatological diseases: A review of the available literature	29
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting	29
The use of face masks during the COVID ‐19 pandemic in Poland: A survey study of 2315 young adults	29
Possible association between IgA vasculitis and COVID ‐19	29
COVID ‐19 from the perspective of dentists: A case report and brief review of more than 170 cases	28
COVID ‐19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain	28
SARS CoV‐2 aggravates cellular metabolism mediated complications inCOVID‐19 infection	28
COVID‐19 with dermatologic manifestations and implications: An unfolding conundrum	28
Emerging role of anti‐IL23 in the treatment of psoriasis: When humanized is very promising	28
Collision tumors: A review of their types, pathogenesis, and diagnostic challenges	28
Chemical and mechanical characterization of hyaluronic acid hydrogel cross‐linked with polyethylen glycol and its use in dermatology	28
Sudden onset of vitiligo after COVID‐19 vaccine	28
Evaluating hyaluronic acid dermal fillers: A critique of current characterization methods	27
Photodynamic therapy in dermatology: Beyond current indications	27
Telogen effluvium related to post severe Sars‐Cov‐2 infection: Clinical aspects and our management experience	27
Guselkumab: Mid‐term effectiveness, drug survival, and safety in real clinical practice	27

Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?	27
JAK‐inhibitors for dermatomyositis: A concise literature review	27
Cause and management of lipedema‐associated pain	27
A systematic review on mucocutaneous presentations after COVID‐19 vaccination and expert recommendations about vaccination of important immune‐mediated dermatologic disorders	27
Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry	26
Cutaneous manifestations following COVID‐19 vaccination: A report of 25 cases	26
Increased risk of late‐onset, immune‐mediated, adverse reactions related to dermal fillers in patients bearing HLA‐B *08 and DRB1	26
Doxycycline, a widely used antibiotic in dermatology with a possible anti‐inflammatory action against IL ‐6 in COVID ‐19 outbreak	26
Dermatological manifestation of pediatrics multisystem inflammatory syndrome associated with COVID ‐19 in a 3‐year‐old girl	26
Aphthous stomatitis in COVID ‐19 patients: Case‐series and literature review	26
New‐onset lichen planus arising after COVID‐19 vaccination	26
Efficacy and safety of oral minoxidil in female androgenetic alopecia	25
Tumor necrosis factor inhibitors are associated with a decreased risk ofCOVID‐19‐associated hospitalization in patients with psoriasis—A population‐based cohort study	25
Psychodermatological mechanisms of psoriasis	25
Subacute cutaneous lupus erythematosus flare triggered by COVID‐19 vaccine	25
SARS‐CoV‐2 as possible inducer of viral reactivations	25
“Covid arm”: Abnormal side effect after Moderna COVID ‐19 vaccine	25
Scabies: A comprehensive review and current perspectives	25
Evaluation of dermatology consultations in the era of COVID‐19	25
Management of urticaria in COVID ‐19 patients: A systematic review	25
Effectiveness of anti‐interleukin 23 biologic drugs in psoriasis patients who failed anti‐interleukin 17 regimens. A real‐life experience	25
Analysis of dermatologic conditions in Turkey and Italy by using Google Trends analysis in the era of the COVID ‐19 pandemic	25
Management of telogen effluvium during the COVID‐19 emergency: Psychological implications	25
Facial vascular danger zones for filler injections	24
Topical treatment for plantar warts: A systematic review	24
Pityriasis rosea‐like cutaneous eruption as a possible dermatological manifestation after Oxford‐AstraZeneca vaccine: Case report and brief literature review	24
The use of human acellular dermal matrices in advanced wound healing and surgical procedures: State of the art	24
Recurrent aphthous stomatitis: A comprehensive review and recommendations on therapeutic options	24
Mask‐induced Koebner phenomenon and its clinical phenotypes: A multicenter, real‐life study focusing on 873 dermatological consultations during COVID‐19 pandemics	24
Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis	24
The explosion in scabies cases during COVID ‐19 pandemic	24
Luliconazole‐loaded nanostructured lipid carriers for topical treatment of superficial Tinea infections	24
Exacerbation of plaque psoriasis after inactivated and BNT162b2 mRNA COVID‐19 vaccines: A report of two cases	24
Dermatological diseases presented before COVID ‐19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID	23
Pulsed dye laser followed by intradermal botulinum toxin type‐A in the treatment of rosacea‐associated erythema and flushing	23
Impact on health‐related quality of life and symptoms of anxiety and depression after 32 weeks of Dupilumab treatment for moderate‐to‐severe atopic dermatitis	23
Will teledermatology be the silver lining during and afterCOVID‐19?	23
Pityriasis rosea after Moderna mRNA ‐1273 vaccine: A case series	23
Systematic review of platelet‐rich plasma in treating alopecia: Focusing on efficacy, safety, and therapeutic durability	23
Onset/flare of psoriasis following the ChAdOx1 nCoV ‐19 Corona virus vaccine ( Oxford‐AstraZeneca /Covishield): Report of two case	23
Multicenter study evaluating the impact of COVID ‐19 outbreak on dermatology outpatients in Turkey	23
COVID‐19 induced telogen effluvium	22
Treatments for alopecia areata: A systematic review and network meta‐analysis	22
Cutaneous adverse reactions of COVID ‐19 vaccines: A systematic review	22
Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 nCoV‐19 corona virus vaccine (recombinant)	22
Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16‐week real‐life experience during the COVID ‐19 pandemic in Italy	22
Comprehensive overview of COVID ‐19 based on current evidence	22
Sweet syndrome after Oxford‐AstraZeneca COVID‐19 vaccine (AZD1222) in an elderly female	22
COVID vaccination in patients under treatment with rituximab: A presentation of two cases from Iran and a review of the current knowledge with a specific focus on pemphigus	22
Janus kinase inhibitors for treatment of morphea and systemic sclerosis: A literature review	22
Cutaneous adverse events related to COVID ‐19 vaccines: A cross‐sectional questionnaire‐based study of 867 patients	22
Apremilast in dermatology: A review of literature	22
COVID‐19 and impact of personal protective equipment use: From occupational to generalized skin care need	22
Progression of mycosis fungoides after treatment with dupilumab: A case report	22
Psoriasis andCOVID‐19: A narrative review with treatment considerations	22
Psychodermatology of skin picking (excoriation disorder): A comprehensive review	22
Anti‐IL17 and anti‐IL23 biologic drugs for scalp psoriasis: A single‐center retrospective comparative study	22
Alopecia areata in a COVID‐19 patient: A case report	21
Systematic review of low‐dose isotretinoin for treatment of acne vulgaris: Focus on indication, dosage, regimen, efficacy, safety, satisfaction, and follow up, based on clinical studies	21
Isotretinoin and the eye: A review for the dermatologist	21
What the physicians should know about mast cells, dendritic cells, urticaria, and omalizumab duringCOVID‐19 or asymptomatic infections due toSARS‐CoV‐2?	21
New emergent therapies for atopic dermatitis: A review of safety profile with respect to female fertility, pregnancy, and breastfeeding	21
Benefits of topical hyaluronic acid for skin quality and signs of skin aging: From literature review to clinical evidence	21
Surveillance of psoriatic patients on biologic treatment during the COVID‐19 pandemic: A single‐center experience	20
An overview of treatment options for mild‐to‐moderate acne based on American Academy of Dermatology, European Academy of Dermatology and Venereology, and Italian Society of Dermatology and Venereology	20
Patients with specific skin disorders who are affected by COVID ‐19: What do experiences say about management strategies? A systematic review	20
The efficacy of energy‐based devices combination therapy for melasma	20
Cutaneous manifestations of COVID ‐19: A review of the published literature	20
Changing paradigms of dermatology practice in developing nations in the shadow of COVID ‐19: Lessons learnt from the pandemic	20
Acute generalized exanthematous pustulosis after COVID ‐19 treatment with hydroxychloroquine	20
A systematic review on treatment‐related mucocutaneous reactions in COVID ‐19 patients	20
The use of guselkumab 100 mg every 4 weeks on patients with hidradenitis suppurativa and a literature review	20
Female pattern hair loss: A comprehensive review	20
The effectiveness of combination therapies for androgenetic alopecia: A systematic review and meta‐analysis	20
Micro needling: A novel therapeutic approach for androgenetic alopecia, A Review of Literature	20
The manifestation of oral mucositis in COVID ‐19 patients: A case‐series	20
SARS‐CoV‐2 vaccination‐induced cutaneous vasculitis: Report of two new cases and literature review	20
Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors	20
Contact dermatitis due to masks and respirators during COVID ‐19 pandemic: What we should know and what we should do	20
A daily regimen of a ceramide‐dominant moisturizing cream and cleanser restores the skin permeability barrier in adults with moderate eczema: A randomized trial	20

New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection	19
Maculopapular skin eruptions associated with Covid‐19: A systematic review	19
Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight in the COVID‐19 era	19
Change of the diagnostic distribution in applicants to dermatology after COVID ‐19 pandemic: What it whispers to us?	19
A significant reduction in the diagnosis of melanoma during the COVID‐19 lockdown in a third‐level center in the Northern Italy	19
Tetracyclines in COVID ‐19 patients quarantined at home: Literature evidence supporting real‐world data from a multicenter observa	19
Laser tattoo removal: Fundamental principles and practical approach	19
Challenges in sarcoidosis and sarcoid‐like reactions associated to immune checkpoint inhibitors: A narrative review apropos of a case	19
Lichen planus and lichen planopilaris flare after COVID ‐19 vaccination	19
Generalized pustular psoriasis following COVID ‐19	18
The efficacy of fractional CO 2 laser in acne scar treatment: A meta‐analysis	18
Diagnostic and prognostic values of cutaneous manifestations in COVID ‐19	18
Exacerbation of psoriasis following COVID ‐19 vaccination in a patient previously treated with PD ‐1 inhibitor	18
Familial clustering of COVID ‐19 skin manifestations	18
Platelet‐rich plasma—Where do we stand today? A critical narrative review and analysis	18
Tapinarof for the treatment of psoriasis	18
Hidden threat lurking behind the alcohol sanitizers in COVID ‐19 outbreak	18
Microneedling in vitiligo: A systematic review	18
Cutaneous manifestations in COVID ‐19: A skin rash in a child	18
Dupilumab for the treatment of pembrolizumab‐induced bullous pemphigoid: A case report	18
NB‐UVB plus oral Polypodium leucotomos extract display higher efficacy than NB‐UVB alone in patients with vitiligo	18
Skin changes attributed to protective measures againstCOVID‐19: A compilation	18
The impact of COVID ‐19 in patients with psoriasis: A multicenter study in Istanbul	18
Post Covid‐19 vaccination papulovesicular pityriasis rosea‐like eruption in a young male	18
Disease progression and comorbidities in lipedema patients: A 10‐year retrospective analysis	18
Acne treatment review and future perspectives	18
Cutaneous lymphocytic vasculitis after administration of COVID ‐19 mRNA vaccine	17
An updated review of the sebaceous gland and its role in health and diseases Part 1: Embryology, evolution, structure, and function of sebaceous glands	17
Itch in the era of COVID‐19 pandemic: An unfolding scenario	17
Safety of SARS‐CoV‐2 vaccines in psoriatic patients treated with biologics: A real life experience	17
A fatal case of COVID ‐19 infection presenting with an erythema multiforme‐like eruption and fever	17
Azithromycin and COVID‐19: Prompt early use at first signs of this infection in adults and children, an approach worthy of consideration	17
Dermoscopy as a useful tool for evaluating melasma and assessing the response to 1064‐nm Q‐switched Nd: YAG laser	17
The clinical utility of teledermoscopy in the era of telemedicine	17
Serum zinc levels and efficacy of zinc treatment in acne vulgaris: A systematic review and meta‐analysis	17
Effectiveness and safety of guselkumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group	17
Management of psychocutaneous disorders: A practical approach for dermatologists	17
Merkel cell carcinoma: An updated review of pathogenesis, diagnosis, and treatment options	17
Patient‐reported outcomes of topical therapies in actinic keratosis: A systematic review	16
Non‐complicated evolution of COVID ‐19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab	16
Cutaneous and histopathological features of coronavirus disease 2019 in pediatrics: A review article	16
IL‐17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review	16
Different hair loss patterns in two pediatric patients with COVID‐19‐associated multisystem inflammatory syndrome in children	16
Cyclosporin in dermatology: A practical compendium	16
Influence of COVID ‐19 pandemic on hospitalizations at the tertiary dermatology department in south‐west Poland	16
Topical beta‐blockers in dermatologic therapy	16
Dupilumab induces a rapid decrease of pruritus in adolescents: A pilot real‐life study	16
Alopecia areata in a patient with SARS‐Cov ‐2 infection	16
Transverse leukonychia (Mees' lines) nail alterations in a COVID ‐19 patient	16
Omalizumab in children and adolescents with chronic spontaneous urticaria: Case series and review of the literature	16
Evaluation of the laboratory parameters in hidradenitis suppurativa: Can we use new inflammatory biomarkers?	16
Pustular psoriasis exacerbated by COVID ‐19 in a patient with the history of psoriasis	16
Multiple cycles of rituximab therapy for pemphigus: A group of patients with difficult‐ to‐treat disease or a consequence of late rituximab initiation?	16
Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases	16
Activation of Janus kinase signaling pathway in acne lesions	16
Natural products for male androgenetic alopecia	16
Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID ‐19 pandemic: A single‐center real‐life experience	16
Atypical fibroxanthoma: An analysis of 105 tumors	16
Immunosuppressive drugs for patients with psoriasis during the COVID ‐19 pandemic era. A review	16
Dimethyl fumarate treatment for psoriasis in a real‐life setting: A multicentric retrospective study	16
Drug survival of dupilumab compared to cyclosporin in moderate‐to‐severe atopic dermatitis patients	15
High‐sensitivity C‐reactive protein as a biomarker in detecting subclinical atherosclerosis in psoriasis	15
Hair‐pulling disorder (Trichotillomania): Etiopathogenesis, diagnosis and treatment in a nutshell	15
Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib	15
Certolizumab pegol for hidradenitis suppurativa: Case report and literature review	15
Oral cyclosporine is effective in stabilizing active vitiligo: Results of a randomized controlled trial	15
Acute localized exanthematous pustulosis: Clinical features, pathophysiology, and therapy	15
Topical antibiotics in the dermatological clinical practice: Indications, efficacy, and adverse effects	15
Dermatological findings in patients admitting to dermatology clinic after using face masks during Covid‐19 pandemia: A new health problem	15
Livedoid vasculopathy in 75 Brazilian patients in a single‐center institution: Clinical, histopathological and therapy evaluation	15
Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID‐19	15
Risankizumab shows high efficacy and maintenance in improvement of response until week 52	15
Treatment of cutaneous viral warts in children: A review	15
Efficacy and safety of Risankizumab in moderate to severe psoriasis: A systematic review and meta‐analysis	15
Systemic isotretinoin therapy in the era of COVID‐19	15
PG‐TIME : A practical approach to the clinical management of pyoderma gangrenosum	15
A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: Clinical, histopathological, and physicochemical study	15
Favorableeffect of creams with skimmed donkey milk encapsulated in nanoliposomes on skin physiology	15
Dupilumab combined with low‐dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid	15
A 24‐weeks real‐world experience of dupilumab in adolescents with moderate‐to‐severe atopic dermatitis	15
Changing trends in dermatology practice during COVID ‐19 pandemic: A single tertiary center experience	15
Cross sectional quality of life assessment in patients with androgenetic alopecia	15
Alopecia areata as an immune‐related adverse event of immune checkpoint inhibitors: A review	15
Topical dermocosmetics and acne vulgaris	15
Bullous pemphigoid triggered by COVID ‐19 vaccine: Rapid resolution with corticosteroid therapy	15
Topical and oral minoxidil for hair disorders in pediatric patients: What do we know so far?	15
Habit reversal therapy in the management of body focused repetitive behavior disorders	15
Telemedicine approach for psoriasis management, time for application? A systematic review of published studies	14
Platelet‐rich plasma for androgenetic alopecia: Efficacy differences between men and women	14
Does therapy with biological drugs influence COVID ‐19 infection? Observational monocentric prevalence study on the clinical and epidemiological data of psoriatic pa	14
Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review	14
Aggressive course of pemphigus vulgaris followingCOVID‐19 infection	14
Successful treatment of pityriasis rubra pilaris with guselkumab: Serum CCL20 as a potential marker for the disease activity	14
Propranolol for infantile hemangioma: Evaluating efficacy and predictors of response and rebound growth	14
Sequential paradoxical psoriasiform reaction and sacroiliitis following adalimumab treatment of hidradenitis suppurativa, successfully treated with guselkumab	14